- ホーム
- > 洋書
- > ドイツ書
- > Mathematics, Sciences & Technology
- > Medicine & Pharmacy
- > general medicine, diagnostics, therapy, basics
基本説明
New in paperback. Hardcover was published in 2007. In this most comprehensive reference source for the development, production and therapuetic application of antibodies, Volume I contains general chapters presenting established technologies and clinical applications. Volume II provides a look at emerging technologies, new therapeutic concepts, and clinical studies. The third volume feature detailed and specific information about each currently approved type of antibody, including the clinical data.
Description
(Review)
"...Das dreibändige Werk ist wirklich ausgesprochen gut gelungen...Jedem, der sich mit Antikörpern beschäftigt, ist dieses Buch wärmstens zu empfehlen." Pharmazie in unserer Zeit, 09/2007
(Text)
In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume 1 contains general chapters on the development, production, and therapeutic antibodies as well as providing a look at emerging technologies and future developments. The second volume includes one chapter devoted to each currently approved type of antibody, including the clinical data, as well as overview chapters on those antibodies that are still undergoing clinical trials.A must-have handbook meeting the needs of both basic and applied research as well as of the pharmaceutical and biotech industries.
(Table of content)
VOLUME I: TECHNOLOGIESNew Therapeutic ConceptsExtraction and PurificationMolecular EngineeringProductionSelection SystemsClinical StudiesEmerging TechnologiesFuture Developments of Research and ApplicationVOLUME II: APPROVED THERAPEUTICS A-MAbciximabAdalimumabAlemtuzumabBasiliximabDaclizumabGemtuzumabInfliximabVOLUME III: APPROVED THERAPEUTICS N-Z, THERAPEUTICS IN CLINICL TRIALOmalizumabPalivizumabRituximabTrastuzumabVotumumabAntibodies in Phase I/II for Cancer TherapyAntibodies in Phase I/II for Infectious DiseasesAntibodies in Phase I/II for Autoimmune Diseases
(Author portrait)
Stefan Dübel received his PhD at the Center for Molecular Biology Heidelberg and spent his post-doc at the German Cancer Research Center with research on the development of antibody display libraries. In the following years, he substantially participated in the invention of recombinant antibody phage display technology, as well as other recombinant antibody technologies and the development of various antibody fusion proteins. In 1996, he moved to the University of Heidelberg to establish the antibody engineering group at the Institute of Molecular Genetics. After holding a group leader position at the University of Heidelberg from 1996, Stefan Dübel went to the Biological Faculty of the Technical University of Braunschweig as a full professor in 2002. Here, he currently serves as head of the Department of Biotechnology in Braunschweig and managing director of the Institute of Biochemistry and Biotechnology. He has co-authored more than 90 scientific papers, 17 patents, as well astwo acknowledged textbooks in the field of recombinant antibodies. He is also board member of scientific journals and the biotech industry.
